<?xml version="1.0" encoding="UTF-8"?>
<p id="p0050">A commercial vaccine (Bioaftogen®, batch #688, Biogénesis Bagó, Argentina) consisted in a water-in-oil single emulsion containing the four FMDV strains O1 Campos, A24 Cruzeiro, A/Argentina/2001, and C3 Indaial with an antigen concentration greater than 30 µg per dose. The vaccine batch was examined by the Argentina National Food Safety and Quality Service (SENASA) and complied with requirements for safety, purity, and potency (in cattle) before its release to the market 
 <xref rid="b0045" ref-type="bibr">[9]</xref>, 
 <xref rid="b0050" ref-type="bibr">[10]</xref>. The vaccine batch has been approved with an expected percentage of protection (EPP) of 96.3%, 95.7%, 98.0%, and 98.4% for O1 Campos, A24 Cruzeiro, A/Argentina/2001, and C3 Indaial vaccine strains, respectively, and has been applied in Argentine vaccination campaigns. Vaccination was performed using a single dose of 2 ml via the intramuscular route into the neck with 15-gauge, 18-mm needles on 10 ml disposable syringes.
</p>
